Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lobby advocates for venture capitalists, startups

This article was originally published in The Tan Sheet

Executive Summary

Frustrated by the lack of attention innovators and startups received during the health care reform debate, the National Venture Capital Association forms a group to speak up for the groups in national affairs. NVCA announced Sept. 7 its Medical Innovation and Competitiveness will push for more recognition for startups developing devices and therapeutics and the investors that back them. Kelly Slone, director of the NVCA's medical industry group, said, "No one is paying attention to these little companies and they're the ones really driving innovation." The coalition will push for a presidentially appointed position to assess the impact of new federal policies on medical innovation. With medical and biopharma startups already squeezed in capital markets, new uncertainties emerge from health care reform and a lack of predictability in the regulatory and reimbursement realms

You may also be interested in...



FDA Talks Tough On Complete Response Extensions

The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.

Stada Names New Global Development Head

Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.

Coronavirus Update: Pfizer Urged To Delay Vaccine Submission

A letter from more than 60 leading public health and medical ethics experts has been sent to Pfizer's CEO Albert Bourla.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel